Shares of Guided Therapeutics Inc. (OTC: GTHP), developer of a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that uses light to detect disease at the cellular level, are soaring in trading today.
At last check, GTHP shares were trading 22.08% higher at $0.940 on above average volume of 430,882. The stock touched an intra-day high of $0.96 in trading today.
GTHP shares are soaring in trading today after the company announced the received notification that its LuViva® Advanced Cervical Scan has been granted CE Mark approval. LuViva Advanced Cervical Scan is a non-invasive device used to detect cervical disease that leads to cancer, instantly and at the point of care.
With the CE Mark approval, GTHP will now be able to sell LuViva in the European Union.
Mark L. Faupel, Ph. D., President and CEO of Guided Therapeutics, said that the notification of CE Mark for LuViva is a major milestone for the company and allows it to begin its European launch later this year, as planned. Faupel said that the company believes that together with its distributors, it has tremendous opportunity to improve the detection of cervical disease, reduce false positives and unnecessary biopsies and provide substantial savings to healthcare systems throughout Europe.